Immuneering Corporation appointed Grant C. Bogle, MBA, as a Class III Director on November 9, 2026. He will receive compensation under the company’s arrangements for non-employee directors and has not joined a board committee.
IMRX · Immuneering Corp
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Immuneering raised the MAPKeeper 301 enrollment target from 510 to approximately 570 patients, ahead of schedule, keeping topline data planned for mid-2028. Net loss was $54.9 million for the nine months ended September 30, 2026, with $166.1 million in cash, cash equivalents and marketable securities. Cash is now expected to fund operations into the fourth quarter of 2028, previously into 2029.
Immuneering said MAPKeeper 301 enrollment is ahead of schedule, expanding the Phase 3 trial to approximately 570 patients and potentially accelerating mid-2028 topline data. Cash runway guidance was updated to the fourth quarter of 2028.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Atebimetinib-treated patients in ctDNA analysis | 123 | second quarter 2026 | — |
| Evaluable patients weight stable or gaining weight at 3 months (atebimetinib + mGnP) | 84% | second quarter 2026 | — |
| Phase 2a first-line pancreatic cancer patients treated with atebimetinib + mGnP | 55 | second quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IMRX
this stock
Immuneering Corp
|
$220.84M | -46.8% | -100.0% | — | 22.5% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 15
Immuneering Corporation appointed Grant C. Bogle, MBA, as a Class III Director on November 9, 2026. He will receive compensation under the company’s arrangements for non-employee directors and has not joined a board committee.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IMRX | -7.7% | -6.4% | -39.3% | -6.5% | -46.8% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -3.8% | -0.9% | -35.9% | -3.2% | -53.9% |